About Journal of Clinical OncologyJCO is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). Published thrice monthly, JCO is the foremost peer-reviewed journal focusing on clinical cancer research and the authoritative source for current information on the diagnosis and treatment of patients with cancer.Why publish in Journal of Clinical Oncology?We offer rapid publication, high visibility, and the opportunity to have your research widely read.Speed of publication Average time from submission to first decision is just 10 days. Articles are published online first, weeks ahead of issue publication. A Rapid Communications program that fast-tracks important research.Impact and reach Cited more than 133,000 times in 2014—ranked #1 among all clinical oncology journals.(1) 2014 ISI Impact Factor: 18.443(1) Eigenfactor Rank: #1(1) Google Scholar h5-index Rank: #1(2) Over 6.6 million full-text article request each year. Read by more than 25,000 oncologists in over 120 countries. Accessed by nearly 10,000 academic, corporate, and government institutions worldwide.Benefits of partnering with ASCO Gain instant recognition by publishing with ASCO, the most trusted source in oncology information. Have your article promoted via ASCO publications, websites, and social media. Take advantage of immediate open access options for your manuscript.The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.The acceptance rate for Original Reports is 13%.JCO is published three times per month -- a total of 36 issues per year.JCO provides free, or significantly discounted, online access to public health institutions in more than 100 developing countries through the World Health Organization''''s Health InterNetwork Access to Research Initiative (HINARI). Through HINARI, JCO aims to strengthen public health services by providing public health workers, researchers, and policy makers access to high-quality, relevant, and timely medical information.

關于臨床腫瘤學雜志JCO是美國臨床腫瘤學會(ASCO)的主要科學論壇。JCO每月出版三次，是最重要的同行評審期刊，專注于臨床癌癥研究和權威來源的最新信息診斷和治療癌癥患者。為什么要發表在臨床腫瘤學雜志上?我們提供快速出版，高能見度，并有機會讓您的研究廣泛閱讀。出版速度從提交到第一次決定的平均時間只有10天。文章首先在網上發表，比發表時間提前幾周。快速跟蹤重要研究的快速通信程序。影響和達到2014年被引用13.3萬余次，在所有臨床腫瘤學期刊中排名第一。2014 ISI影響因子:18.443(1)特征因子排名:# 1 (1)谷歌Scholar h5索引排名:#1(2)每年有超過660萬篇全文要求。超過120個國家的25000名腫瘤學家閱讀了這本書。全球近10,000個學術、企業和政府機構訪問。與ASCO合作的好處通過與ASCO，腫瘤學信息中最值得信賴的來源合作，獲得即時的認可。通過ASCO出版物、網站和社交媒體來推廣你的文章。利用即時開放的選項為您的手稿。臨床腫瘤學雜志為其讀者提供最可靠、最權威的資源，以傳播重要的臨床腫瘤學研究。在印刷和電子格式，JCO致力于出版最高質量的文章致力于臨床研究。最初的報告仍然是JCO關注的焦點，但是通過適當選擇與癌癥患者護理相關的社論、評論、評論和其他工作，這種科學交流得到了加強。原始報告的通過率為13%。JCO每月出版三次，每年出版36期。JCO通過世界衛生組織的衛生互聯網絡研究倡議(HINARI)向100多個發展中國家的公共衛生機構提供免費或大幅折扣的在線訪問。通過HINARI, JCO旨在通過向公共衛生工作者、研究人員和決策者提供高質量、相關和及時的醫療信息來加強公共衛生服務。